Emmaus Life Sciences Inc. (EMMA)

2.77  -1.72 (-38.31%)

After market: 2.73 -0.04 (-1.44%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

Emmaus Life Sciences Inc.

NASDAQ:EMMA (9/10/2019, 7:00:00 PM)

After market: 2.73 -0.04 (-1.44%)

2.77

-1.72 (-38.31%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap131.48M
Shares
PEN/A
Fwd PEN/A
Dividend Yield0%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

EMMA Daily chart

Company Profile

Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.

Company Info

Emmaus Life Sciences Inc.

21250 Hawthorne Boulevard Suite 800

Torrance CA 90503

P: 310-214-0065

CEO: George C. Carpenter

EMMA News

News Image14 days ago - Emmaus Life Sciences, Inc.Emmaus Life Sciences Reports Delayed Filing of Annual Report

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

News Image3 months ago - Emmaus Life Sciences, Inc.Emmaus Life Sciences recibe la autorización de comercialización para Puerto Rico

/PRNewswire-HISPANIC PR WIRE/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), líder en el tratamiento de la anemia falciforme, también denominada enfermedad de...

News Image3 months ago - Emmaus Life Sciences, Inc.Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease (SCD) treatment, today announced that it has received marketing...

News Image6 months ago - Emmaus Life Sciences, Inc.Emmaus Life Sciences Reports Q3 2023 Financial Results

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

News Image8 months ago - Emmaus Life Sciences, Inc.Emmaus Life Sciences Reports Management Changes

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

News Image9 months ago - Emmaus Life Sciences, Inc.Emmaus Life Sciences Reports Q2 2023 Financial Results

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA Twits

Here you can normally see the latest stock twits on EMMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example